Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 26 of 36 / 848 articles
Public health communication about nicotine has prioritized simplicity over accuracy. The result is a public that doesn't understand the risk continuum—and smokers who don't know that switching could save their lives.
A statistical portrait of the tobacco epidemic: the billion smokers, the 7 million annual deaths, the trillions in economic costs. The numbers tell a story that words alone cannot.
Getting smokers from 20 cigarettes a day to 2 is a public health triumph. Getting from 2 to zero is a personal battle that policy alone can't win. The 'last mile' of smoking cessation deserves more attention.
After hundreds of articles and thousands of pages, what are the essential lessons of the nicotine debate? Ten takeaways that distill the evidence, the arguments, and the human dimensions.
One hundred more articles on nicotine. The landscape hasn't resolved—it's deepened. The evidence has accumulated, the arguments have evolved, and the central challenge remains unchanged.
From 'ENDS' to 'harm reduction' to 'PMTA,' the nicotine debate has a specialized vocabulary. Here's a glossary of key terms, with definitions that acknowledge the controversies behind them.
A concise, evidence-based briefing on the nicotine landscape, designed for the people who make the decisions. What's the evidence, what's the uncertainty, and what are the policy options?
What are the most urgent unanswered questions in nicotine science? A research agenda for the next decade, organized by the questions whose answers would most affect policy and practice.
What do nicotine users themselves think about the policies that affect them? Their voices are rarely heard in the policy debate—but they should be.
The series concludes—and the story continues. A final look forward at the forces, the evidence, and the choices that will shape the nicotine landscape in the years ahead.
The UK embraces vaping. Australia bans it. The U.S. is somewhere in between. The global nicotine regulatory landscape is fragmenting, not converging. Why—and what happens next?
Nicotine is used to treat smoking addiction—and it's the substance that causes smoking addiction. It enhances cognition and impairs development. It's the central paradox of the nicotine debate.
Nicotine use, cessation, and harm are not evenly distributed across space. From the rural smoking belt to the urban vaping hub, geography is destiny for nicotine users—and policy needs to reflect that.
Strip away the rhetoric, the institutional positions, and the statistical arguments. What are the fundamental questions at the heart of the nicotine debate? Seven questions that frame everything else.
The denormalization of smoking was a public health triumph. But it had a shadow side: the stigmatization of smokers. Shame, it turns out, is not an effective cessation strategy.
Sometimes a picture is worth a thousand words—or a thousand articles. Five data visualizations that capture the essence of the nicotine debate more clearly than any prose.
Philip Morris says it wants to 'unsmoke the world.' If it succeeds, what kind of company will it become—and can it be trusted to manage the transition it claims to be leading?
The standard answer—'because they're addicted to nicotine'—is true but incomplete. People smoke for reasons that are social, psychological, cultural, and economic. Addressing smoking requires understanding all of them.
Overwhelmed by the nicotine evidence? Here's a curated guide to the most important studies, reviews, and reports—organized by topic, with context on what each contributes and what it leaves open.
The series concludes—not because the topic is exhausted, but because every inquiry must have an ending. A final reflection on nicotine, evidence, policy, and the human capacity for change.
Projecting forward from 2026: the products, the policies, the culture, and the health outcomes of the nicotine world two decades from now. A speculative but evidence-grounded forecast.
To the readers of 2035 and beyond: this is what we knew, what we argued about, and what we hoped for. May you have resolved the debates we couldn't.
Nicotine policy involves trade-offs between competing values: autonomy vs. protection, present vs. future, individual vs. population. An ethical framework for navigating these trade-offs.
From Stockholm to Shenzhen to São Paulo, the nicotine transition is unfolding differently in every corner of the world. A global tour reveals both the diversity of experience and the common challenges.
Products
Select a product to view details, highlights, and technical specifications.
